Coroflex please
WebAs a subsidiary brand of the Coroplast Group, the WeWire business unit works worldwide on innovative solutions for the automotive industry. With around 8400 employees at currently 8 production sites and customer-oriented service centers, we … WebNational Center for Biotechnology Information
Coroflex please
Did you know?
WebAug 26, 2013 · Coroflex Please (B Braun, Melsungen, Germany) is a newly developed PES. We compared the clinical and angiographic efficacy of Coroflex Please with Taxus Liberte (Boston Scientific, Natick, MA) in a real-world practice. WebCoroflex, a subsidiary of the Coroplast Group, develops and produces wire and cable solutions for the Automotive, Industrial, and Mechanical Engineering sectors. ... Please call or write to us if you have any …
WebCoroflex Global China Poland WeWire Global China Poland Select language English Deutsch Contact us +49 202 2681 0; [email protected]; Search Search ... WebOct 23, 2009 · Coroflex Please stent is a newly developed drug eluting stent using the Coroflex stent platform combined with the drug paclitaxel contained in a polymer coating.
WebJun 18, 2008 · Patients will be randomized according to the type of drug eluting stent ( CoroflexTM Please vs. TaxusTM). Randomization will also be stratified per hospital for the presence of DM and the presence of long lesions (lesion length > 28mm) Patient Enrollment :915 patients enrolled at 13 centers in Korea. Patient Follow-Up WebMay 1, 2013 · The Coroflex Please is a 120-μm-thick 316-L stainless steel stent coated with a layer of the nonresorbable polymer polysulfone and paclitaxel with a dose of 1 …
WebOct 23, 2009 · Coroflex Please (B Braun, Melsungen, Germany) is a newly developed PES. We compared the clinical and angiographic efficacy of Coroflex Please with Taxus Liberte (Boston Scientific, Natick, MA) in ...
Webon the market is the the SeQuent™ Please device, a coronary balloon catheter that combines balloon angioplasty with local delivery of paclitaxel. In several small, but … geoff britten american ninja warrior winWebMethods: The Coroflex(®) Please Registry was an international, prospective, multicenter registry enrolling patients with symptomatic ischemic heart disease. The primary endpoint was clinically driven target lesion revascularization (TLR) at 9 months. Secondary endpoints were technical success, in-hospital outcomes, definite stent thrombosis ... geoff breton actorWebBackground and Objectives: Various active stent coatings significantly reduce restenosis rates and target lesion revascularization compared to bare metal stents.Therefore, the … chris layne milligan universityWebAug 27, 2012 · The Coroflex ® Please Registry was an international, prospective, multicenter registry enrolling patients with symptomatic ischemic heart disease. The … chris layton attorneyWebWe report on a young patient with ST-elevation myocardial infarction (STEMI) who presented to our emergency department arising from very late stent thrombosis (VLST) of a 2.5 × 28 mm paclitaxel-eluting stent (Coroflex ® Please) three years after its implantation. After the patient was treated with balloon dilation, intravascular ultrasound ... geoff britten american ninja castle rockWebComparison of the efficacy and safety of paclitaxel-eluting coroflex please stents and paclitaxel-eluting stents in patients with coronary artery disease: A randomized PIPA trial Article Nov 2012 geoff britten t shirtWebThis 'all comers' registry assessed the 10-month outcome of the Coroflex(®) Please drug-eluting stent in Europe and Asia by clinically driven major adverse cardiac events. Methods: The primary endpoint was clinically driven target lesion revascularization (TLR) at 9 months. geoff britten american ninja warrior